News
Chromoplexy linked to aggressive Ewing sarcomas
Analysis of the sequence context surrounding chromoplexy breaks may provide clues and potentially point to a therapeutic vulnerability that could...
News
Valsartan recalls: FDA, manufacturers issue advisories
To address concerns regarding the voluntary recall of some valsartan products, affected drugmakers and the FDA have issued advisories for...
News
FDA approves vaginal ring contraceptive Annovera
The first vaginal ring contraceptive that can be used for 1 year has been approved by the Food and Drug Administration.
News
FDA approves Nivestym, second biosimilar to Neupogen
Nivestym (filgrastim-aafi), a biosimilar to Neupogen (filgrastim) was approved July 20 by the FDA.
News
Essure sales to halt in U.S. by end of 2018
According to the FDA, Bayer stated its decision to halt sales and distribution of the device was because of commercial reasons.
News
FDA announces plan for biosimilar innovation and competition
One proposed step is to release a series of videos that explain key concepts about biosimilar and interchangeable products.
News
DESMOPAZ: Pazopanib slows disease progression of desmoid tumors
Pazopanib elicited clinically meaningful responses in adults with progressive desmoid tumors according to RECIST 1.1 criteria, based on two...
News
Metastatic soft tissue sarcomas respond to anlotinib
Anlotinib was confirmed to be safe and effective for soft tissue sarcoma patients who have progressed after first-line chemotherapy, based on...
News
REGOBONE: Regorafenib shows efficacy in metastatic osteosarcoma
Regorafenib appears to be active in patients with metastatic osteosarcomas, based on results from REGOBONE a non-comparative phase 2, double-blind...
News
Sorafenib boosts PFS in desmoid tumor patients
Sorafenib was well tolerated with significantly improved progression-free survival in select patients with desmoid tumors, reported Mrinal M....
News
SARCO24: Regorafenib falls short for treatment-refractory liposarcoma
Regorafenib fell short of improving progression-free survival in patients with treatment-refractory liposarcomas, Richard Reidel, MD, of Duke...
News
EPAZ: Pazopanib matches doxorubicin without the neutropenia in elderly patients
Pazopanib can be considered as a first line alternative treatment to doxorubicin in patients over age 60 with advanced, inoperable soft tissue...
News
ENLIVEN: Pexidartinib improves symptoms, function in patients with advanced tenosynovial giant cell tumors
Pexidartinib significantly improved overall response rates and functioning in patients with advanced tenosynovial giant cell tumors (TGCT), based...
News
FDA approves Doptelet for liver disease patients undergoing procedures
Avatrombopag (Doptelet) is the first drug approved for thrombocytopenia in adults who have chronic liver disease and are undergoing a procedure....